Related Experiment Video
Updated: Feb 21, 2026
Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
Published on: May 2, 2025
PD-1 blockade therapy in lymphoid malignancies
Momoko Nishikori1, Akifumi Takaori-Kondo1
1Department of Hematology/Oncology, Graduate School of Medicine, Kyoto University.
Abstract:
The programmed cell death-1 (PD-1) pathway serves as a checkpoint for suppressing T cell-mediated immune responses. It regulates both the physiological and pathological functions of T cells and is often involved as a mechanism of tumor immune evasion. Many clinical trials have demonstrated that blockade of PD-1 and its ligands is a promising therapeutic strategy for various kinds of malignancies. The most prominent results of PD-1 blockade therapy have been shown in clinical studies of classical Hodgkin lymphoma (cHL), and the PD-1 inhibitor nivolumab was approved for treatment of relapsed/refractory cHL in Japan at the end of 2016. There is increasing evidence that PD-1 blockade therapy is also effective in several other subtypes of lymphoid malignancies. PD-1 inhibitors demonstrate a favorable safety profile, but they can cause immune-related adverse events that affect a variety of organs, such as skin, lung, thyroid, and intestine. Although infrequent, they can develop into life-threatening conditions, and specific monitoring is recommended for the early detection and treatment of these uncommon side effects during PD-1 blockade therapy.
Insights
Blockading the programmed cell death-1 (PD-1) pathway is a promising cancer therapy, especially for lymphomas. While effective, PD-1 inhibitors can cause rare but serious immune-related side effects requiring monitoring.
Area of Science:
- Immunology
- Oncology
- Pharmacology
Background:
- The programmed cell death-1 (PD-1) pathway is a critical immune checkpoint that regulates T cell responses.
- Tumor cells exploit the PD-1 pathway for immune evasion, hindering anti-tumor immunity.
- PD-1 blockade has emerged as a significant therapeutic strategy in oncology.
Purpose of the Study:
- To review the efficacy and safety of PD-1 blockade therapy in lymphoid malignancies.
- To highlight the clinical success in classical Hodgkin lymphoma (cHL) and other lymphoid cancers.
- To discuss the potential immune-related adverse events (irAEs) associated with PD-1 inhibitors.
Main Methods:
- Review of clinical trial data and scientific literature on PD-1 blockade therapy.
- Analysis of treatment outcomes in various lymphoid malignancies.
- Evaluation of the safety profile and irAEs of PD-1 inhibitors.
Main Results:
- PD-1 blockade therapy shows significant efficacy in classical Hodgkin lymphoma (cHL), leading to drug approval.
- Evidence suggests effectiveness in other lymphoid malignancies beyond cHL.
- PD-1 inhibitors generally have a favorable safety profile, but irAEs affecting multiple organs can occur.
Conclusions:
- PD-1 blockade is a valuable therapeutic approach for lymphoid malignancies.
- Early detection and management of immune-related adverse events are crucial for patient safety.
- Continued research is warranted to optimize PD-1 blockade strategies and manage side effects.
More Related Videos
06:07Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
Published on: February 5, 2020
10:18Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
Published on: July 7, 2023
